Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
96
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Considerations for the Utility of Real-World Evidence Beyond Trial Data in Advanced NSCLC: The Case of Frontline Tyrosine Kinase Inhibitors

Priyanka Gaitonde1 AstraZeneca, Health Economics & Payer Evidence, Gaithersburg, MD, USACorrespondence[email protected]
View further author information
,
Viktor Chirikov2 OPEN Health Evidence & Access, Bethesda, MD, USAView further author information
,
Sneha Kelkar2 OPEN Health Evidence & Access, Bethesda, MD, USAView further author information
&
Bengt Liljas1 AstraZeneca, Health Economics & Payer Evidence, Gaithersburg, MD, USAORCID Iconhttps://orcid.org/0000-0002-9411-7087View further author information
ORCID Icon
Pages 3421-3435 | Received 28 Jul 2022, Accepted 27 Oct 2022, Published online: 27 Nov 2023

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (1)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.